Whittier Trust Co. of Nevada Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 11.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 157,699 shares of the company’s stock after selling 20,896 shares during the quarter. Johnson & Johnson comprises approximately 1.9% of Whittier Trust Co. of Nevada Inc.’s holdings, making the stock its 5th largest position. Whittier Trust Co. of Nevada Inc.’s holdings in Johnson & Johnson were worth $16,498,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. raised its stake in Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Boston Partners raised its stake in Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares during the last quarter. Cornerstone Wealth Management LLC raised its stake in Johnson & Johnson by 10,307.6% during the 2nd quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after purchasing an additional 2,473,105 shares during the last quarter. Bank of Montreal Can raised its stake in Johnson & Johnson by 36.1% during the 2nd quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares during the last quarter. Finally, Summit Trail Advisors LLC raised its stake in Johnson & Johnson by 11,692.6% during the 1st quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after purchasing an additional 1,752,841 shares during the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.
Shares of Johnson & Johnson stock opened at $133.87 on Friday. The firm has a market capitalization of $370.70 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 2.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.04. The firm had revenue of $20.83 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.83 EPS. Analysts expect that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Insiders own 0.22% of the company’s stock.
Several equities analysts recently commented on the stock. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a research note on Friday, September 14th. Finally, Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $143.91.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Cash Flow
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.